Site scheduled for expansion (yellow boxed area)
AGC invertirá 100 millones en su planta de Cataluña y contratará 100 personas en 2024
The project of this Spanish and Japanese small molecule CDMO (Contract Development & Manufacturing Organization) will bring an investment of 100 million US dollars, increasing a 30% API production capacity and creating 100 new jobs by first half of 2024.
Barcelona, April 6, 2022 – AGC Pharma Chemicals, based in Spain and Japan, manufacturing small molecule Active Pharmaceutical Ingredients (APIs) and intermediates, has decided to expand even more the site of Malgrat de Mar, Barcelona.
The expansion of the CDMO means a 7,500 square meters floor of building area and the implementation of new reactors with a volume from 1.5 to 7.5 m3, including the production capability to handle pharmaceutical compounds HPAPIs. In addition, the company has already planned another important investment soon, and for that the new building will have additional space for this future project.
In terms of Sustainability, as a member of the Responsible Care® Program, a global chemical industry’s voluntary initiative, AGC Pharma Chemicals will build up and operate the new plant minimizing its impacts to the community and the environment.
Also, the enterprise has recently invested in a larger R&D building, in the transformation to multi-purpose concept plant and in a micronizer unit. Thanks to all these projects, the CDMO company will be fully capable of producing a wide range of APIs and intermediates, offering the knowledge of handling flourine as one of their services.
The small molecule CDMO market is growing at over 7% annually, while the number of contracts handled by the companies are growing at an even faster rate. With this capacity expansion AGC Pharma Chemicals is prepared to satisfy this strong demand of the industry, focusing on their mission: to improve people´s life by bringing their best quality products.
AGC Pharma Chemicals Europe es una organización global de desarrollo y fabricación por contrato (CDMO), con sede en España y Japón, que fabrica principios activos farmacéuticos (API) e intermedios. La empresa cuenta con un sólido crecimiento comercial y estabilidad financiera como parte del AGC Group. ith solid business growth and financial stability as a part of AGC Group.
AGC Group es un grupo empresarial global con más de 200 empresas, con 55.900 empleados en más de 30 países. En 2021 tuvo un total de ventas netas de 12.731 millones de euros (JPY 120 = €1).
Under its medium-term management plan AGC plus-2023, the AGC Group has positioned its Life Science business, including its small molecule CDMO services, as one of its strategic businesses.